STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HORSHAM, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2022.

STRATA Skin Sciences Reports First Quarter 2022 Financial Results

HORSHAM, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its first quarter 2022 financial results on Wednesday, May 11, 2022. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report First Quarter 2022 Financial Results on May 11, 2022

HORSHAM, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of various autoimmune skin diseases, today announced that it has become a corporate sponsor of the Global Vitiligo Foundation (GVF). Vitiligo, which affects approximately seventy million people in the world1, is an autoimmune skin disease in which the skin loses pigment cells called melanocytes, resulting in discolored white or pink patches of skin in different areas of the body.

STRATA Skin Sciences Becomes Corporate Sponsor of the Global Vitiligo Foundation

HORSHAM, Pa., March 28, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

STRATA Skin Sciences to Participate in the Lytham Partners Spring 2022 Investor Conference

NextDecade

Tellurian

Here's what you need to know about trading penny stocks on March 25th The post Trading Penny Stocks? Top Stock Market News for March 24th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 24th, 2022

LiveOne

NexImmune

NextNav

Red Cat Holdings

The Dow Jones surged around 350 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Insiders Buying These 5 Penny Stocks

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 33.33% and 0.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates

STRATA Skin Sciences, Inc.'s (SSKN) CEO Robert Moccia on Q4 2021 Results - Earnings Call Transcript

HORSHAM, Pa., March 21, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021.

STRATA Skin Sciences Reports Record Fourth Quarter 2021 Revenue

Announces Participation in the 2022 American Academy of Dermatology Meeting Announces Participation in the 2022 American Academy of Dermatology Meeting

STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations

HORSHAM, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter and full year 2021 financial results on Monday, March 21, 2022. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

STRATA Skin Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 21, 2022

HORSHAM, Pa., March 03, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer 32nd Annual Healthcare Conference.

STRATA Skin Sciences to Participate in the Upcoming Oppenheimer 32nd Annual Healthcare Conference

HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors.

STRATA Skin Sciences Appoints Patricia S. Walker, M.D.

HORSHAM, Pa., Feb. 09, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced its commercial launch, with the first installation in the U.S. market, of its next generation excimer laser system, XTRAC Momentum™ 1.0.

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum™ 1.0 and First Installation in the U.S.

Enables STRATA to Commercialize and Market its XTRAC Excimer Lasers to an Estimated 300,000 Psoriasis and 160,000 Vitiligo Patients in Israel Enables STRATA to Commercialize and Market its XTRAC Excimer Lasers to an Estimated 300,000 Psoriasis and 160,000 Vitiligo Patients in Israel

STRATA Skin Sciences Expands into Israel with Leading Medical Device Distributor

STRATA Skin Sciences Inc (NASDAQ: SSKN) expects Q4 FY21 sales of $8.8 million - $9.2 million, compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $29.7 million - $30.1 million (compared to a consensus of $29.11 million), up from $23.1 million in FY20.

STRATA Skin Sciences Acquires Theravant's Acne Treatment Device, Expects Upside Q4 Sales

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today reported preliminary, unaudited fourth quarter 2021 financial results.

STRATA Skin Sciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that it has entered into a definitive agreement to acquire assets related to Theravant Corporation's TheraClear System. Theravant develops and markets a novel, FDA-cleared, system for the in-office treatment of many common forms of acne. This acquisition enables STRATA's expansion into the acne treatment market.

STRATA Skin Sciences Announces Acquisition of Acne Treatment Device Assets from Theravant Corporation

HORSHAM, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that members of Management will participate in the upcoming H.C. Wainwright Bioconnect Virtual Conference.

STRATA Skin Sciences to Present at the H.C. Wainwright Bioconnect Virtual Conference

HORSHAM, Pa., Dec. 09, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021. Mr. Strang will assume the role of Audit Committee Chair upon the departure of LuAnn Via, who will step down from the Board on December 31, 2021 as part of a planned transition.

STRATA Skin Sciences Announces Board of Directors Transition

STRATA Skin Sciences, Inc. (SSKN) CEO Robert Moccia on Q3 2021 Results - Earnings Call Transcript

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and -0.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Misses Revenue Estimates

HORSHAM, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended September 30, 2021.

STRATA Skin Sciences Reports Third Quarter 2021 Financial Results

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strata Skin Sciences, Inc. (SSKN) Report Negative Earnings Next Week? What You Should Know

HORSHAM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its third quarter 2021 financial results after the market closes on Wednesday, November 10, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

News for STRATA Skin Sciences Stock (SSKN)